{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:01:17Z","timestamp":1777604477834,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03162-2","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T08:43:49Z","timestamp":1743324229000},"page":"2490-2499","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Different Definitions of Vaso-Occlusion on Efficacy Assessments in Sickle Cell Disease Clinical Trials"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0590-2826","authenticated-orcid":false,"given":"Haydar","family":"Frangoul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Eckrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzan","family":"Imren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengjuan","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"3162_CR1","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","volume":"4","author":"GJ Kato","year":"2018","unstructured":"Kato GJ, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"3162_CR2","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJMra1510865","volume":"376","author":"FB Piel","year":"2017","unstructured":"Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376(16):1561\u201373.","journal-title":"N Engl J Med"},{"issue":"10091","key":"3162_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","volume":"390","author":"RE Ware","year":"2017","unstructured":"Ware RE, et al. Sickle cell disease. Lancet. 2017;390(10091):311\u201323.","journal-title":"Lancet"},{"key":"3162_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","volume":"14","author":"P Sundd","year":"2019","unstructured":"Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019;14:263\u201392.","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"3162_CR5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ajh.27164","volume":"99","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, et al. Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing. Am J Hematol. 2024;99(3):430\u20138.","journal-title":"Am J Hematol"},{"issue":"7","key":"3162_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/1535370216640385","volume":"241","author":"CT Quinn","year":"2016","unstructured":"Quinn CT. Minireview: clinical severity in sickle cell disease: the challenges of definition and prognostication. Exp Biol Med (Maywood). 2016;241(7):679\u201388.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"3162_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. N Engl J Med. 2021;384(3):252\u201360.","journal-title":"N Engl J Med"},{"issue":"7","key":"3162_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2117175","volume":"386","author":"J Kanter","year":"2022","unstructured":"Kanter J, et al. Biologic and clinical efficacy of lentiglobin for sickle cell disease. N Engl J Med. 2022;386(7):617\u201328.","journal-title":"N Engl J Med"},{"key":"3162_CR9","doi-asserted-by":"crossref","unstructured":"Hanna R, Frangoul H, McKinney C, Pineiro C, Mapara M, Dalal J, Rangarajan H, Atkins H, Chang K-H, Jaskolka M, Kim K, Mei B, Afonja O, Walters MC. Reni-cel, an investigational AsCas12a gene-edited cell medicine, led to sustanined hemoglobin normalization and increased fetal hemoglobin in patients with severe sickle cell disease treated in the RUBY trial. In: ASH 2024 Poster Presentation, 2024.","DOI":"10.1182\/blood-2024-210343"},{"issue":"20","key":"3162_CR10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","volume":"332","author":"S Charache","year":"1995","unstructured":"Charache S, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317\u201322.","journal-title":"N Engl J Med"},{"issue":"5","key":"3162_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","volume":"376","author":"KI Ataga","year":"2017","unstructured":"Ataga KI, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429\u201339.","journal-title":"N Engl J Med"},{"issue":"3","key":"3162_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1715971","volume":"379","author":"Y Niihara","year":"2018","unstructured":"Niihara Y, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226\u201335.","journal-title":"N Engl J Med"},{"issue":"6","key":"3162_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1903212","volume":"381","author":"E Vichinsky","year":"2019","unstructured":"Vichinsky E, et al. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019;381(6):509\u201319.","journal-title":"N Engl J Med"},{"issue":"18","key":"3162_CR14","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","volume":"390","author":"H Frangoul","year":"2024","unstructured":"Frangoul H, et al. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med. 2024;390(18):1649\u201362.","journal-title":"N Engl J Med"},{"issue":"5","key":"3162_CR15","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2011-01-332510","volume":"118","author":"MM Hsieh","year":"2011","unstructured":"Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood. 2011;118(5):1197\u2013207.","journal-title":"Blood"},{"key":"3162_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/asheducation-2011.1.273","volume":"2011","author":"S Shenoy","year":"2011","unstructured":"Shenoy S. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends. Hematol Am Soc Hematol Educ Program. 2011;2011:273\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03162-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03162-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03162-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:50:44Z","timestamp":1744872644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03162-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3162"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03162-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Haydar Frangoul has been a consultant for Editas Medicine, Rocket Pharmaceuticals, and Vertex Pharmaceuticals; served on a data monitoring and safety committee for Rocket Pharmaceuticals; served on a steering committee for Vertex Pharmaceuticals; and has received honoraria from Jazz Pharmaceuticals. Franco Locatelli has been a consultant for Amgen, Bellicum Pharmaceuticals, Novartis, Novimmune, and Sobi, Inc; speaker bureau for Bluebird bio and Gilead Sciences; and served on a steering committee for Vertex Pharmaceuticals. Michael Eckrich has been a member of an advisory board for Vertex Pharmaceuticals. Suzan Imren, Nanxin Li, and Fengjuan Xuan are employees of Vertex Pharmaceuticals Incorporated and may hold stock and\/or stock options in the company. Stephan Grupp has been a consultant for Novartis, Jazz, Adaptimmune, Allogene, Cabaletta, Verismo, Eureka, and Vertex Pharmaceuticals; received honoraria and research funding from Novartis; served on the advisory boards\/committees for Allogene and McKesson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The CLIMB SCD-121 trial was conducted in accordance with the Declaration of Helsinki, local applicable laws and regulations, and current Good Clinical Practice Guidelines as described by the International Council for Harmonization. Each patient or patient\u2019s legal guardian provided informed consent, with assent obtained when age appropriate. An independent data-monitoring committee is reviewing safety data throughout the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}